{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:35:29Z","timestamp":1789684529363,"version":"4.0.1"},"reference-count":29,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The objective was to review the safety and efficacy of daprodustat, a hypoxia-inducible factor\u2013prolyl hydroxylase inhibitor (HIF-PHI) in the treatment of anemia of chronic kidney disease (CKD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was conducted in MEDLINE, EMBASE, and ClinicalTrials.gov using the keywords \u201cdaprodustat,\u201d \u201cGSK1278863,\u201d and \u201chypoxia-inducible factor-prolyl hydroxylase inhibitors\u201d from January 2010 through November 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Literature was included if it evaluated pharmacology, pharmacokinetics, efficacy, and\/or safety of daprodustat in human subjects and was reported in English. The manufacturer\u2019s product monograph was also utilized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>Daprodustat significantly increased hemoglobin levels in CKD patients on dialysis (difference 0.18 g\/dL) and not on dialysis (difference 0.08 g\/dL) over 52-week treatment periods compared with erythropoiesis stimulating agents (ESA) in Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat (ASCEND)-D and ASCEND-ND, respectively. First occurrence of major adverse cardiovascular events (MACEs) was similar between daprodustat and ESAs in both trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs:<\/jats:title>\n                    <jats:p>Daprodustat can be used in patients with CKD on dialysis and already receiving an ESA for at least 6 weeks to further increase serum hemoglobin levels without increasing the risk of MACE. Adverse effects of daprodustat that may occur more than ESAs include headache, emesis, and thrombosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241241563","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T02:05:36Z","timestamp":1713146736000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Daprodustat: A Hypoxia-Inducible Factor\u2013Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4724-8364","authenticated-orcid":false,"given":"Haley N.","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, University of Health Sciences & Pharmacy in St. Louis, St. Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Prasad-Reddy","sequence":"additional","affiliation":[{"name":"Office of Medical Education, Chicago Medical School, Rosalind Franklin University of Medicine and Science, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,4,14]]},"reference":[{"key":"bibr1-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2021.11.003"},{"key":"bibr2-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2017.07.007"},{"key":"bibr3-10600280241241563","unstructured":"Shaikh H, Hashmi MF, Aeddula NR. Anemia of chronic renal disease. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2023. Accessed December 15, 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK539871\/."},{"key":"bibr4-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-022-02778-8"},{"key":"bibr5-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"issue":"4","key":"bibr6-10600280241241563","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/kisup.2012.33","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"bibr7-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1016\/j.kisu.2020.12.002"},{"key":"bibr8-10600280241241563","unstructured":"Jesduvroq (daprodustat) [package insert]. Durham, NC: GlaxoSmithKline; 2023. Accessed December 15, 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216951s000lbl.pdf."},{"key":"bibr9-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113379"},{"key":"bibr10-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.117.242503"},{"key":"bibr11-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2015.193"},{"key":"bibr12-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfy014"},{"key":"bibr13-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13686"},{"key":"bibr14-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2113380"},{"key":"bibr15-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013751.pub2"},{"key":"bibr16-10600280241241563","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1131516"},{"key":"bibr17-10600280241241563","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204611"},{"key":"bibr18-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13385"},{"key":"bibr19-10600280241241563","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00550122"},{"key":"bibr20-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035938"},{"key":"bibr21-10600280241241563","unstructured":"Seo J, Lewis J. Final summary minutes of the cardiovascular and renal drugs advisory committee meeting October 26, 2022. FDA. October 22, 2022. Accessed December 1, 2023. https:\/\/www.fda.gov\/media\/163406\/download."},{"key":"bibr22-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.02.019"},{"key":"bibr23-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2022.0605"},{"key":"bibr24-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1159\/000513103"},{"key":"bibr25-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2025956"},{"key":"bibr26-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab057"},{"key":"bibr27-10600280241241563","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020081150"},{"key":"bibr28-10600280241241563","unstructured":"Centers for Medicare & Medicaid Services. Calendar year 2023 end-stage renal disease (ESRD) prospective payment system (PPS) final rule (CMS-1768-F). October 31, 2022. Accessed December 1, 2023. https:\/\/www.cms.gov\/newsroom\/fact-sheets\/calendar-year-2023-end-stage-renal-disease-esrd-prospective-payment-system-pps-final-rule-cms-1768-f."},{"key":"bibr29-10600280241241563","unstructured":"Hiemstra T, Vick JG, Roberts JC. Anemia studies in CKD: erythropoiesis via a novel PHI daprodustat\u2014pediatric (ASCEND-P). NCT: 05682326. Updated December 22, 2023. Accessed February 27, 2024. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05682326?term=NCT05682326&rank=1."}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241241563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241241563","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241241563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:39Z","timestamp":1777374819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241241563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1177\/10600280241241563"],"URL":"https:\/\/doi.org\/10.1177\/10600280241241563","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,14]]}}}